NCT03760445 - HDM201 Added to CT in R/R or Newly Diagnosed AML | Biotech Hunter

Timeline

Start Date

November 15, 2019

Primary Completion Date

July 22, 2021

Study Completion Date

June 13, 2023

Conditions

Leukemia, Myeloid, Acute

Interventions

DRUG

HDM201

2.5 mg and 10mg capsules, given orally

DRUG

cytarabine

20mg or 1000 mg or other strengths as locally available given intravenously

DRUG

anthracycline

20mg or other strength as locally available given intravenously

DRUG

midostaurin

25mg capsules given orally

DRUG

liposomal cytarabine/daunorubicin

100mg/44mg or other strength as locally available given intravenously

DRUG

posaconazole

100mg delayed release tablet or other strength as locally available given orally

DRUG

midazolam

2mg/mL oral solution or in other strength as locally available